This document summarizes the ATMOSPHERE trial which tested whether combining the renin inhibitor aliskiren with the ACE inhibitor enalapril was superior to enalapril alone in patients with heart failure. The trial found no benefit to adding aliskiren to enalapril and aliskiren alone was not proven to be no worse than enalapril alone. The combination led to more adverse effects without additional clinical benefits. The results do not support using aliskiren in addition to or as an alternative to ACE inhibitors for heart failure patients.
Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. Study assessing the morbi-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease ( SIGNIFY)
http://www.theheart.org/web_slides/1425587.do
A randomized to placebo or ivabradine study on Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) with patients on standard HF medications according to guidelines
Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomised double-blind placebo-controlled international multicentre study. Study assessing the morbi-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease ( SIGNIFY)
http://www.theheart.org/web_slides/1425587.do
A randomized to placebo or ivabradine study on Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) with patients on standard HF medications according to guidelines
The natriuretic peptide system works antagonistically to the RAAS and has favorable effects on the pathogenesis of heart failure
Natriuretic peptides are broken down by an enzyme called neprilysin
Neprilysin is also responsible for the breakdown of other substances, including bradykinin and angiotensin II
Sacubitril/valsartan is a combination product
Sacubitril is a pro-drug that, upon activation, acts as a neprilysin inhibitor
It works by blocking the action of neprilysin, thus preventing the breakdown of natriuretic peptides
This leads to a prolonged duration of the favorable effects of these peptides
The natriuretic peptide system works antagonistically to the RAAS and has favorable effects on the pathogenesis of heart failure
Natriuretic peptides are broken down by an enzyme called neprilysin
Neprilysin is also responsible for the breakdown of other substances, including bradykinin and angiotensin II
Sacubitril/valsartan is a combination product
Sacubitril is a pro-drug that, upon activation, acts as a neprilysin inhibitor
It works by blocking the action of neprilysin, thus preventing the breakdown of natriuretic peptides
This leads to a prolonged duration of the favorable effects of these peptides
Recent Advancements in the treatment of Hypertension.Akshata Darandale
Uncontrolled blood pressure had become most common cause of death accounting for more than 7 million deaths per year worldwide. Despite the availability of potent lifestyle and pharmacologic approaches, rates of control of blood pressure are unsatisfactory and additional strategies to curb the burden of hypertension are warranted. Several novel pharmacological and device-based approaches have recently been tested and may prove helpful to achieve better blood pressure control rates and thereby improve cardiovascular outcomes in patients with hypertension.
Angiotensin neprilysin inhibition in acute decompensated heart failureShadab Ahmad
Sacubitril–valsartan is an angiotensin receptor– neprilysin inhibitor that is indicated for the treatment of patients with symptomatic heart failure with reduced ejection fraction
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Francesca Gottschalk - How can education support child empowerment.pptx
Atmosphere
1.
2. AIM
• To test whether combining the renin inhibitor aliskiren with the ACE
inhibitor enalapril was superior to enalapril alone and whether
aliskiren was at least noninferior to enalapril in patients with heart
failure
3.
4. RAAS INHIBITORS IN HF
ACE Inhibitors
• CONSENSUS
• SOLVED
ARBS
• CHARM ALTERNATIVE
• ELITE-II
ACEI vs ARBS vs COMBINATION
• VALIANT
ALISKIREN
• ALTITUDE
• ASTROUNAUT
• ATMOSPHERE
5. ACE Inhibitors and ARBs
• incomplete RAAS blockade
• reduced feedback inhibition of renin release, triggering a reactive rise in PRA
ACE Inhibitor
• reactive rise in PRA causes a compensatory increase in Ang I which partially
restores Ang II production by ACE-dependent and ACE-independent pathways
• Causes dry cough and angioedema
ARB
• reactive rise in plasma renin activity causes compensatory increases in both Ang I
and Ang II
• latter may partially restore AT II type 1 receptor stimulation and stimulate
profibrotic AT type 2 receptors and prothrombotic AT type 4 receptor
16. ALTITUDE Trial
• Aliskiren increases the risk of adverse events and stroke without any
cardiovascular or renal improvements in patients with Type 2
Diabetes
• trial was stopped prematurely
17.
18. ASTRONAUT trial
aliskiren to standard HHF therapy in non-diabetic patients
• well-tolerated and improves post-discharge outcomes and biomarker
profiles.
diabetic patients receiving aliskiren
• worse post-discharge outcomes.
19. The Aliskiren Trial to Minimize Outcomes in
Patients with Heart Failure (ATMOSPHERE)
• randomized trial comparing enalapril alone with aliskiren alone and
with the combination of aliskiren and enalapril in patients with heart
failure
• March 13, 2009, to December 26, 2013
• median follow-up was 36.6 months
20. ELIGIBLE PATIENTS
1. chronic heart failure with NYHA class II to IV symptoms and an EF
≤35%
2. plasma BNP ≥ 150 pg /ml (or NT-proBNP≥600 pg /ml)
3. if they had been hospitalized for heart failure within the previous 12
months, a BNP ≥ 100 pg /ml (or an NT-proBNP ≥400 pg /ml).
4. receiving stable doses of an ACE inhibitor (equivalent to at least 10 mg
of enalapril daily) and of a beta-blocker at the time of enrollment.
21. EXCLUSION CRITERIA
1. symptomatic hypotension
2. SBP <95 mm Hg at screening (or <90 mm Hg at randomization),
3. eGFR < 40 ml / minute / 1.73 m2 at screening (or <35 ml / minute / 1.73 m2 at
randomization or a decline of >25% in eGFR between screening and randomization)
4. serum potassium ≥ 5.0 mmol / liter at screening (or ≥5.2 mmol /liter at randomization)
5. history of inability to take ACE inhibitors
22. • patients were assigned to the combination of enalapril at a dose of 5
or 10 mg twice daily and aliskiren at a dose of 150 mg once daily,
aliskiren at a dose of 150 mg once daily, or enalapril at a dose of 5 or
10 mg twice daily.
• Two weeks after randomization, the dose of aliskiren was increased
to 300 mg once daily in the combination-therapy group and the
aliskiren group, with sham adjustment in the enalapril group
23. OUTCOMES
primary outcome
• composite of death from
cardiovascular causes or a first
hospitalization for heart failure
secondary outcomes
• change from baseline to 12
months in the Kansas City
Cardiomyopathy Questionnaire
(KCCQ) clinical summary score
• change in the NT-proBNP
concentration from baseline to
4 months
24. • ALTITUDE &ASTRONAUT Trials -led to mandate that persons with
diabetes at baseline and those in whom diabetes developed during
the present trial discontinue the treatment and be switched to
conventional therapy and that no further patients with diabetes be
enrolled
25.
26.
27.
28.
29.
30.
31. DISCUSSION
patients with heart failure in which the addition of an ARB to an ACE
inhibitor was of some benefit in previous trials
more likely explanation is that neither earlier trial required an
evidence-based dose of ACE inhibitor, whereas our trial did
absence of additional benefit with combination therapy in our study
was not due to a lack of incremental inhibition of RAAS, because the
addition of aliskiren to enalapril led to more adverse effects that are
indicative of greater blockade of this system.
32. similar excess of adverse effects was noted when only half the full dose of
valsartan was added to an evidence-based dose of captopril in patients
after MI
there is a therapeutic ceiling for blockade of RAAS beyond which there is
little or no additional efficacy and only more adverse effects.
despite the high rate of discontinuation of the randomly assigned therapy
by the end of the trial, overall exposure to the treatment was satisfactory
We did not identify worse outcomes in the patients with diabetes who
were treated with combination therapy than in those who were treated
with enalapril alone.
Patients with diabetes who were treated with aliskiren monotherapy had
outcomes similar to those of patients treated with enalapril.
33. CARRY HOME MESSAGE
no benefit from the addition of a renin inhibitor to an
evidence-based dose of enalapril
not support the use of a renin inhibitor as an
alternative to an ACE inhibitor, because the
prespecified criterion for noninferiority was not met.